NIH to Grant Exclusive License for VEGF and FGF Peptides for Cardiovascular Disease

Summary

The National Institutes of Health is considering granting a domestic exclusive license to Collateral Therapeutics to use VEGF and FGF peptides for treating cardiovascular conditions such as myocardial ischemia.